Home
About
Capabilities
R&D
Investors
News
Careers
中文
Home
About
Capabilities
R & D
Investors
News
Careers
Press Release
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
Mar 25, 2024
Mabwell ranks on the list of 2024 Top 100 Hardcore Technology Enterprises in Shanghai
➞
Mar 18, 2024
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London
➞
Mar 18, 2024
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
➞
Mar 15, 2024
Mabwell has been included in the FTSE Russell Global Equity Index Series
➞
Mar 11, 2024
Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London
➞
Mar 07, 2024
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
➞
Mar 06, 2024
Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer
➞
Feb 25, 2024
FDA Grants Fast Track Designation to 9MW2821
➞
Feb 19, 2024
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
➞
Feb 18, 2024
FDA Grants Orphan Drug Designation to 9MW3011
➞
1
2
下一页
开元体育(中国)官方网站
|
亚搏官方娱乐
|
乐动在线·(中国)官方网站
|
开云app中国官方网站(中国)科技公司
|
爱游戏官网登录
|
华体会官方网站-华体会(中国)
|
韦德官方网站
|
欧宝app官方入口
|
hg8888皇冠
|